Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Latest updates in molecular testing in NSCLC
Date
14 Sep 2020Session
Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencingPresenters
Justin GainorAuthors
J.F. GainorAuthor affiliations
- Thoracic Oncology, Massachusetts General Hospital, Boston/US
Resources
Resources from the same session
Welcome and introduction
Presenter: Rosario Garcia Campelo
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast
EGFR+ NSCLC: A personalised sequencing approach
Presenter: Jesus Corral Jaime
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast
ALK+ and ROS1+ NSCLC: Optimising patient outcomes
Presenter: Todd Bauer
Session: Pfizer Oncology - Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing
Resources:
Webcast